Healthcare Utilization and Costs for Musculoskeletal Disorders in Ontario, Canada

J. Power, A. Perruccio, J. Paterson, M. Canizares, C. Veillette, P. Coyte, E. Badley, N. N. Mahomed, Y. R. Rampersaud
{"title":"Healthcare Utilization and Costs for Musculoskeletal Disorders in Ontario, Canada","authors":"J. Power, A. Perruccio, J. Paterson, M. Canizares, C. Veillette, P. Coyte, E. Badley, N. N. Mahomed, Y. R. Rampersaud","doi":"10.3899/jrheum.210938","DOIUrl":null,"url":null,"abstract":"Objective. To examine the magnitude and costs of ambulatory primary care, specialist physician care, and hospital service use for musculoskeletal disorders (MSDs) in Canada’s largest province, Ontario. Methods. Administrative health databases were analyzed for fiscal year 2013–2014 for adults aged ≥ 18 years, including data on physician services, emergency department (ED) visits, and hospitalizations. International Classification of Diseases diagnostic codes were used to identify MSD services. A validated algorithm was used to estimate direct medical costs. Person-visit rates and numbers of persons and visits were tabulated by care setting, age, sex, and physician specialty. Data were examined for all MSDs combined, as well as for specific diagnostic groupings. Results. Overall, 3.1 million adult Ontarians (28.5%) made over 8 million outpatient physician visits associated with MSDs. These included 5.6 million primary care visits. MSDs accounted for 560,000 (12.3%) of all adult ED visits. Total costs for MSD-related care were $1.6 billion, with 12.6% of costs attributed to primary care, 9.2% to specialist care, 8.6% to ED care, 8.5% to day surgery, and 61.2% associated with inpatient hospitalizations. Costs due to arthritis accounted for 40% of total MSD care costs ($639 million). MSD-related imaging costs were $169 million, yielding a total cost estimate of $1.8 billion for MSDs overall. Conclusion. MSDs place a significant and costly burden on the healthcare system. Health system planning needs to consider the large and escalating demand for care to reduce both the individual and population burden.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.210938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Objective. To examine the magnitude and costs of ambulatory primary care, specialist physician care, and hospital service use for musculoskeletal disorders (MSDs) in Canada’s largest province, Ontario. Methods. Administrative health databases were analyzed for fiscal year 2013–2014 for adults aged ≥ 18 years, including data on physician services, emergency department (ED) visits, and hospitalizations. International Classification of Diseases diagnostic codes were used to identify MSD services. A validated algorithm was used to estimate direct medical costs. Person-visit rates and numbers of persons and visits were tabulated by care setting, age, sex, and physician specialty. Data were examined for all MSDs combined, as well as for specific diagnostic groupings. Results. Overall, 3.1 million adult Ontarians (28.5%) made over 8 million outpatient physician visits associated with MSDs. These included 5.6 million primary care visits. MSDs accounted for 560,000 (12.3%) of all adult ED visits. Total costs for MSD-related care were $1.6 billion, with 12.6% of costs attributed to primary care, 9.2% to specialist care, 8.6% to ED care, 8.5% to day surgery, and 61.2% associated with inpatient hospitalizations. Costs due to arthritis accounted for 40% of total MSD care costs ($639 million). MSD-related imaging costs were $169 million, yielding a total cost estimate of $1.8 billion for MSDs overall. Conclusion. MSDs place a significant and costly burden on the healthcare system. Health system planning needs to consider the large and escalating demand for care to reduce both the individual and population burden.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
加拿大安大略省肌肉骨骼疾病的医疗保健利用和成本
目标。在加拿大最大的省份安大略省,研究针对肌肉骨骼疾病(MSDs)的门诊初级保健、专科医生护理和医院服务使用的规模和成本。方法。对2013-2014财政年度18岁以上成人的行政卫生数据库进行分析,包括医生服务、急诊(ED)就诊和住院数据。国际疾病分类诊断代码用于确定MSD服务。采用经过验证的算法估算直接医疗费用。根据护理环境、年龄、性别和医生专业,将患者访视率和人数制成表格。检查了所有MSDs的综合数据,以及特定的诊断分组。结果。总体而言,310万成年安大略人(28.5%)与msd相关的门诊医生访问量超过800万次。其中包括560万次初级保健就诊。在所有成人急诊科就诊中,msd占56万例(12.3%)。msd相关护理的总成本为16亿美元,其中12.6%用于初级保健,9.2%用于专科护理,8.6%用于急诊科护理,8.5%用于日间手术,61.2%用于住院治疗。关节炎的费用占MSD总护理费用的40%(6.39亿美元)。与msd相关的成像成本为1.69亿美元,msd的总成本估计为18亿美元。结论。msd给医疗保健系统带来了巨大而昂贵的负担。卫生系统规划需要考虑到对保健的巨大且不断上升的需求,以减轻个人和人口负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
The Journal of rheumatology. Supplement
The Journal of rheumatology. Supplement Medicine-Medicine (all)
自引率
0.00%
发文量
0
期刊介绍: The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
期刊最新文献
Cluster Analysis To Explore Clinical Subphenotypes Of Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis. Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with Livedo. Dr. Trefond et al reply: Giant Cell Arteritis After SARS-CoV-2 Vaccination-Coincidence or Trigger ?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1